UA98666C2 - Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method - Google Patents

Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method

Info

Publication number
UA98666C2
UA98666C2 UAA201003471A UAA201003471A UA98666C2 UA 98666 C2 UA98666 C2 UA 98666C2 UA A201003471 A UAA201003471 A UA A201003471A UA A201003471 A UAA201003471 A UA A201003471A UA 98666 C2 UA98666 C2 UA 98666C2
Authority
UA
Ukraine
Prior art keywords
oxalic acid
medicinal preparation
treatment method
malignant cells
action against
Prior art date
Application number
UAA201003471A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Геннадий Васильевич Мазильников
Аркадий Петрович Шиманский
Юрий Анатольевич Лиходид
Стефания Стефановна Мельник
Original Assignee
Геннадий Васильевич Мазильников
Аркадий Петрович Шиманский
Юрий Анатольевич Лиходид
Стефания Стефановна Мельник
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Геннадий Васильевич Мазильников, Аркадий Петрович Шиманский, Юрий Анатольевич Лиходид, Стефания Стефановна Мельник filed Critical Геннадий Васильевич Мазильников
Priority to UAA201003471A priority Critical patent/UA98666C2/en
Priority to PCT/UA2010/000015 priority patent/WO2011119126A1/en
Publication of UA98666C2 publication Critical patent/UA98666C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

The invention relates to medicine, in particular to methods for the treatment of oncological diseases, and concerns a medicinal preparation comprising oxalic acid, lithium chloride, as well as dimethylxanthine, fluorouracil and sodium bisulphate.
UAA201003471A 2010-03-25 2010-03-25 Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method UA98666C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
UAA201003471A UA98666C2 (en) 2010-03-25 2010-03-25 Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method
PCT/UA2010/000015 WO2011119126A1 (en) 2010-03-25 2010-03-26 Use of oxalic acid in the production of a therapeutic preparation with anti-tumour activity in relation to malignant cells, a therapeutic preparation based thereon and a method of treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201003471A UA98666C2 (en) 2010-03-25 2010-03-25 Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method

Publications (1)

Publication Number Publication Date
UA98666C2 true UA98666C2 (en) 2012-06-11

Family

ID=44673473

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003471A UA98666C2 (en) 2010-03-25 2010-03-25 Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method

Country Status (2)

Country Link
UA (1) UA98666C2 (en)
WO (1) WO2011119126A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074055A1 (en) * 2011-11-16 2013-05-23 ШИМАНСКИЙ, Аркадий Петрович Method for restoring and rejuvenating the human body and a pharmaceutical composition for implementation thereof
RU2712443C1 (en) * 2018-12-14 2020-01-29 Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук Cocrystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133317A (en) * 1995-11-15 2000-10-17 Hart; Francis J. Oxalic acid or oxalate composition and method of treatment
AU2003270202A1 (en) * 2002-09-17 2004-04-08 Centre National De La Recherche Scientifique Pharmaceutical compositions increasing camp useful for the treatment of cancers
BRPI0511780A (en) * 2004-06-03 2008-01-15 Hoffmann La Roche oxoliplatin treatment and an egrf inhibitor
ZA200701578B (en) * 2004-07-23 2008-09-25 Om Pharma Combination anticancer therapy and pharmaceutical compositions therefore
CN101657203B (en) * 2007-03-02 2012-09-05 卧龙岗大学 Compositions and methods for delivery of anti-cancer agents

Also Published As

Publication number Publication date
WO2011119126A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
PH12015501344A1 (en) Zinc amino acid halide complex with cysteine
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
AU2011328009A8 (en) Compounds and methods for treating pain
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX2015017036A (en) Method for producing renal precursor cells, and drug containing renal precursor cells.
GB201106743D0 (en) Novel compounds
WO2012129341A3 (en) Disease detection in plants
EP2626071A4 (en) Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MX364220B (en) Methods of treating fibrosis.
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
EP2659894A4 (en) Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
SG195127A1 (en) Methods of treating or preventing neurological diseases
WO2012048330A3 (en) Treatment of motor neuron disease
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
SG195170A1 (en) Methods of treating or preventing rheumatic disease
PL2859092T3 (en) Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1
UA98666C2 (en) Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method
LU91877B1 (en) Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
MX2012012978A (en) Method of producing pleurodesis.
MX351765B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
UA98665C2 (en) Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method
IL234087A0 (en) Ascorbic acid derivative composition and production method of the same, ascorbic acid derivative solution, and skin external preparation
EP2886548A4 (en) Method for producing borinic acid derivative, and novel borinic acid derivative